Fundamental Data for OSCI

OSCIENT PH(NSDQ:OSCI)

Oscient Pharmaceuticals is a biopharmaceutical company committed to the clinical development and commercialization of important new therapeutics to address unmet medical needs.

# Employees: 322

Address: 1000 Winter Street Suite 2200,Waltham,MA,USA

Phone: 781-398-2300

Fax: 781-893-9535

Website: www.investors.oscient.com

Email: investors@genomecorp.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Robert J. Hennessey (Dir.)

David B. Singer (Chmn.; Dir.)

Steven M. Rauscher (Presi.; C.E.O.; Dir.)

Philippe M. Maitre (Sr. V.P.; C.F.O.)

John R. Leone (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 12/31/2008

Next Earnings Date(Expected): 7/24/2009

Mean EPS (Next Qtr): ($0.09)

Mean EPS (Year): ($0.44)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 1

Shares Performance

Period	OSCI	Compare to S&P
YTD	-78.61 %	5.60 %
4 Weeks	-83.89 %	-84.27 %
12 Weeks	-70.38 %	-73.17 %

Shares Information

Analyst Coverage: Y

Avg Volume: 8317794

Shares Outstanding: 39M

Market Cap: $0.00B

52 Week High: $1.49

52 Week Low: $0.04

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 11/16/2006 OSCI split by factor of 0.130

Earnings Performance

EPS Growth in Last Quarter: 93.58 %

EPS Growth in Last Year: 93.52 %

Sales Growth in Last Quarter: 21.22 %

Sales Growth in Last Quarter: 4.44 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010